Tandem Diabetes Care (NASDAQ:TNDM) Advances 4.7% This Week, Taking One-year Gains to 115%
Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target
Tandem Diabetes Care Analyst Ratings
TNDM Stock Likely to Gain From Innovation Amid Competition
Stifel Nicolaus Sticks to Their Buy Rating for Tandem Diabetes Care (TNDM)
Why Tandem Diabetes Care Stock Thrashed the Market Today
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Sector Update: Health Care
Tandem Diabetes Rises as Insulin Pump Cleared for Use in EU With Lilly Insulin
Tandem T:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-rapid Acting Insulin in European Union
Three 'Buys,' Three 'Sells,' and a 'Hold,' by Oppenheimer Analysts
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Morgan Stanley analyst Patrick Wood maintains $Tandem Diabetes Care(TNDM.US)$ with a hold rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 55
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Stifel analyst Mathew Blackman maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 50.5%
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Doing What It Can To Lift Shares
Tandem Diabetes Care Announces Upcoming Conference Participation
Tandem Diabetes a New Equal Weight at Morgan Stanley Due to Competition
Morgan Stanley Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $45
Morgan Stanley analyst Patrick Wood initiates coverage on $Tandem Diabetes Care(TNDM.US)$ with a hold rating, and sets the target price at $45.According to TipRanks data, the analyst has a success
Morgan Stanley Initiates Coverage On Tandem Diabetes Care With Equal-Weight Rating, Announces Price Target of $45
Tandem Diabetes Care Analyst Ratings